Associations of Spatial Disparities of Alzheimer’s Disease Mortality Rates with Soil Selenium and Sulfur Concentrations and Four Common Risk Factors in the United States

2017 ◽  
Vol 58 (3) ◽  
pp. 897-907 ◽  
Author(s):  
Hongbing Sun
2020 ◽  
Vol 185 ◽  
pp. 03031
Author(s):  
Yiyang Xu

Dementia, especially Alzheimer’s dementia, which occupies more than 60% of total dementia cases, has become one of the most significant health problems in the world due to its increasing global prevalence, irreversible pathology, and rising social and economic costs. In this research, the author compared Alzheimer’s disease (AD) prevalence in China and the United States and found the common pattern of its epidemiology. Apart from the quantitative analysis, this research also identifies the pathophysiological, socioenvironmental, and other risk factors of Alzheimer’s disease by qualitative desk research. It was found that the risk factors related to or controlled by genes such as Single Nucleotide Polymorphisms (SNPs) have more influential effects on Alzheimer’s disease onset than the socio-environmental factors. Some socioenvironmental factors such as level of education reflecting the brain activity of a person are also correlated with Alzheimer’s disease prevalence. This disease is caused by an interplay of numerous factors, so there needs to be further investigations into its mechanisms as well as the combination therapy.


2020 ◽  
Vol 30 (4) ◽  
pp. 671-680
Author(s):  
Cara L. Carty ◽  
Carolyn Noonan ◽  
Clemma Muller ◽  
Don Saner ◽  
Eric M. Reiman ◽  
...  

The burden of Alzheimer’s disease and related dementias (ADRD) has increased substantially in the United States, particu­larly in health disparity populations. Little is known about the epidemiology of ADRD in American Indian (AI) adults, although they have a high prevalence of ADRD risk factors including hypertension, diabetes, obesity, and smoking. Using electronic health records from a large health care organization during 2016-18, we describe characteristics of AI patients aged ≥55 years with and without an ADRD diagnosis, assess ADRD risk factors and contrast findings with results from age- and sex-matched non- Hispanic White (NHW) patients. To identify factors associated with ADRD diagnoses, we estimated population-averaged prevalence rate ratios to approximate relative risk (RR) using generalized estimating equations models adjusted for age, sex, and marital and rural residency status. The age-adjusted prevalence of ADRD diagnosis was 6.6% of AI patients, compared with 4.4% in NHW patients. Patient age and diagnosis of hy­pertension, depression, hyperlipidemia, or diabetes were significantly associated with higher risk of ADRD diagnosis in AIs (RR range: 1.1-2.8) whereas female sex or being married/having a partner were associated with lower risk of ADRD diagnosis (each RR=.7). ADRD risk factors were generally similar between AI and NHW patients, except for sex and marital status. However, the adjusted risk of ADRD was approxi­mately 49% higher in AI patients. To our knowledge, our study is the first to examine ADRD diagnoses and comorbidities in AIs across a large geographical region in south­west United States. Future efforts to confirm our findings in diverse AI communities are warranted. Ethn Dis. 2020;30(4):671-680; doi:10.18865/ed.30.4.671


2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Maria Laquaglia ◽  
Marina Celly Martins Ribeiro de Souza ◽  
Carolina Marques Borges

A significant public health concern with regards to increasing rates of Alzheimer’s is that it disproportionately affects minority groups in the United States. The present ecological exploratory study uses secondary aggregate data from the fifty United States. The purpose of this study is to address the disparities in Alzheimer’s in minority populations in the US and explore influencing factors. The “minority” populations considered were African American and Latino populations, and the “majority” population was referred to as “white”. The prevalence rates of Alzheimer’s disease were one-and-a-half times greater, and twice as greater in older Latinos and African Americans respectively, compared to older whites in the investigated time period. The data was extracted from the United States Census Bureau, the CDC National Center for Health Statistics, and the Behavioral Risk Factor Surveillance System (BRFSS) Dataset.  The major results from this study showed that being over 65 years old (p=.009), with a below-average median household income (p=.024), history of stroke (p=.029), and being a part of the Latino population (p=.036), are significantly associated with Alzheimer’s mortality rates in the United States. These findings show an association between Alzheimer’s mortality rates and being a part of a minority population in the United States. By identifying disparities in access to Alzheimer’s healthcare and at-risk communities, more comprehensive intervention strategies can be developed to promote change and advocate for more Alzheimer’s education and resource allocation for minority populations. 


2019 ◽  
Author(s):  
Clemens Kruse ◽  
Britney Larson ◽  
Reagan Wilkinson ◽  
Roger Samson ◽  
Taylor Castillo

BACKGROUND Incidence of AD continues to increase, making it the most common cause of dementia and the sixth-leading cause of death in the United States. 2018 numbers are expected to double by 2030. OBJECTIVE We examined the benefits of utilizing technology to identify and detect Alzheimer’s disease in the diagnostic process. METHODS We searched PubMed and CINAHL using key terms and filters to identify 30 articles for review. We analyzed these articles and reported them in accordance with the PRISMA guidelines. RESULTS We identified 11 technologies used in the detection of Alzheimer’s disease: 66% of which used some form of MIR. Functional, structural, and 7T magnetic resonance imaging were all used with structural being the most prevalent. CONCLUSIONS MRI is the best form of current technology being used in the detection of Alzheimer’s disease. MRI is a noninvasive approach that provides highly accurate results in the diagnostic process of Alzheimer’s disease.


1996 ◽  
Vol 17 (4) ◽  
pp. S95
Author(s):  
L. Hebert ◽  
P. Scherr ◽  
L. Beckett ◽  
D. Evans

2014 ◽  
Vol 10 (2) ◽  
pp. e40-e46 ◽  
Author(s):  
Jennifer Weuve ◽  
Liesi E. Hebert ◽  
Paul A. Scherr ◽  
Denis A. Evans

Author(s):  
Angela M Lunde ◽  
Ronald C Petersen ◽  
John A Lucas

In the United States, the National Alzheimer’s Project Act was signed into law in January 2011, and the first National Plan appeared just over 12 months later, with five goals: to prevent and effectively treat Alzheimer’s disease by 2025, to enhance care quality and efficiency, to expand support for people with Alzheimer’s disease and their families, to enhance public awareness and engagement, and to improve data to track progress. The National Plan has seen a rise in research funding (currently standing at US$1.4 billion). Individual states, at the same time, began discussions about initiatives aimed at addressing personal, societal, and financial implications of Alzheimer’s disease. An example is from Minnesota where counselling and support for caregivers are provided, with an estimated saving for the state of Minnesota of US$970 million by 2025. In addition, a number of treatment trials are under way, looking at the effect of monoclonal antibodies on Alzheimer’s disease and a series of genetic studies.


Sign in / Sign up

Export Citation Format

Share Document